Jan
07
2026
WUN 2026 National Summit Schedule Released
The schedule for Wake Up Narcolepsy’s 2026 National Summit in Chicago, Illinois, has just been...
11:15 /
News
Jan
02
2026
Registration NOW OPEN – 2026 Wake Up Narcolepsy Family Weekend
Join Wake Up Narcolepsy (WUN) at the Center for Courageous Kids (CCK) in Scottsville, Kentucky,...
15:11 /
News
Dec
12
2025
2025 Wake Up Narcolepsy Special Research Update
In 2025, Wake Up Narcolepsy (WUN) donated $170k to Narcolepsy research. This contribution brings the...
08:00 /
News
Dec
06
2025
Wake Up Narcolepsy Featured in 2025 “My Cause My Cleats” NFL Campaign by Nazir Stackhouse
We are honored to share that Green Bay Packers defensive lineman Nazir Stackhouse has selected...
08:00 /
News
Dec
05
2025
Register now for WUN’s 2026 National Summit
Registration is now open for Wake Up Narcolepsy (WUN)’s 2026 National Summit on April 25th...
08:48 /
News
Nov
24
2025
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Nov. 24, 2025-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from...
10:56 /
News
Nov
24
2025
2025 WUN Town Halls Wrap Up
In the second half of the year, Wake Up Narcolepsy (WUN) had nine WUN Town...
08:00 /
News
Nov
21
2025
Future Neurology “Experiences of people with narcolepsy who switched from sodium oxybate to low-sodium oxybate: a plain language summary”
Aatif M. Husain, Phyllis C. Zee, Eileen B. Leary, Douglas S. Fuller, Shawn Candler, Marisa...
09:44 /
News
Nov
19
2025
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Nov. 19, 2025-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the...
13:58 /
News
Nov
14
2025
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
DUBLIN, Nov. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging...
08:06 /
News
